Samrat Pharmachem Complete Financial Statements
In FYNone, Samrat Pharmachem (SAMRATPH) reported revenue ₹295 Cr, net profit ₹-2 Cr and EPS ₹-7.10, with a net profit margin of -1.0% and ROE of -4.4%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SAMRATPH Revenue, Net Profit & EBITDA — Year-on-Year Growth
SAMRATPH YoY (March 2026 vs Period) — revenue +1.4%, net profit +33.3%, EBITDA +100.0%, expenses +1.0%. Compare with SAMRATPH fair value to assess whether the stock is under or overvalued.
SAMRATPH Income Statement — Revenue, EBITDA & Net Profit
Samrat Pharmachem revenue ₹295 Cr, EBITDA ₹0 Cr, net profit ₹-2 Cr, EPS ₹-7.10 (None) — net profit margin -1.0%. For live price, earnings ratios and company overview, see Samrat Pharmachem share price chart.
| Particulars | None | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 295 | 291 | 287 | 283 | 311 | 222 | 180 | 138 | 112 | 93 | 71 | 62 | 48 |
| Expenses | 295 | 292 | 276 | 279 | 287 | 198 | 170 | 131 | 108 | 87 | 67 | 61 | 46 |
| EBITDA | 0 | -1 | 11 | 4 | 24 | 25 | 9 | 7 | 4 | 6 | 4 | 1 | 2 |
| Operating Profit Margin % | -1.00% | -1.00% | 4.00% | 1.00% | 8.00% | 11.00% | 5.00% | 5.00% | 3.00% | 6.00% | 5.00% | 2.00% | 2.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -2 | -3 | 10 | 3 | 23 | 24 | 7 | 6 | 2 | 5 | 3 | 0 | 1 |
| Tax | 0 | 0 | 3 | 0 | 6 | 6 | 2 | 2 | 1 | 2 | 1 | 0 | 0 |
| Net Profit | -2 | -3 | 7 | 2 | 17 | 17 | 5 | 4 | 2 | 3 | 2 | 0 | 0 |
| Earnings Per Share (₹) | -7.10 | -10.72 | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 | 4.97 | 10.41 | 5.68 | 0.97 | 1.02 |
SAMRATPH Balance Sheet — Assets, Liabilities & Shareholders' Equity
SAMRATPH total assets ₹124 Cr, total equity ₹68 Cr, total liabilities ₹ Cr (2026) — ROE -4.4%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 124 | 122 | 122 | 117 | 85 | 57 | 58 | 40 | 41 | 36 | 36 | 26 |
| Current Assets | 104 | 103 | 103 | 99 | 71 | 47 | 50 | 33 | 33 | 28 | 28 | 19 |
| Fixed Assets | 12 | 11 | 11 | 11 | 10 | 9 | 7 | 7 | 7 | 7 | 7 | 7 |
| Capital Work in Progress | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 4 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Other Assets | 108 | 107 | 108 | 104 | 75 | 48 | 50 | 33 | 34 | 29 | 27 | 19 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | 1 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 68 | 72 | 65 | 63 | 47 | 30 | 24 | 20 | 19 | 15 | 14 | 14 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 65 | 69 | 62 | 60 | 44 | 27 | 21 | 17 | 15 | 12 | 11 | 10 |
SAMRATPH Cash Flow Statement — Operating, Investing & Financing
Samrat Pharmachem operating cash flow ₹9 Cr, investing ₹-3 Cr, financing ₹-1 Cr, net cash flow ₹6 Cr (2026).
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 9 | -10 | 9 | -9 | 18 | 5 | -1 | 2 | 0 | -3 | 0 | -1 |
| Investing Activities | -3 | 0 | 0 | -3 | -1 | -3 | -2 | 2 | -2 | 1 | -2 | 0 |
| Financing Activities | -1 | 1 | -11 | 10 | -2 | -2 | 2 | -4 | 2 | 1 | 2 | 0 |
| Net Cash Flow | 6 | -10 | -2 | -3 | 15 | 0 | -1 | 1 | -1 | -1 | 0 | 0 |